Cargando…

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

BACKGROUND: Rapamycin has gained significant attention for its potential activity in reducing the size of TSC-associated tumors, thus providing alternative to surgery. This study aimed at determining the efficacy of rapamycin and rapalogs for reducing the size of TSC-associated solid tumors in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasongko, Teguh Haryo, Ismail, Nur Farrah Dila, Nik Abdul Malik, Nik Mohamad Ariff, Zabidi-Hussin, Z. A. M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531483/ https://www.ncbi.nlm.nih.gov/pubmed/26259610 http://dx.doi.org/10.1186/s13023-015-0317-7

Ejemplares similares

Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy
por: Mohseni, Jafar, et al.
Publicado: (2013)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Permissibility of prenatal diagnosis and abortion for fetuses with severe genetic disorder: type 1 spinal muscular atrophy
por: Sasongko, Teguh H., et al.
Publicado: (2010)

From rapalogs to anti-aging formula
por: Blagosklonny, Mikhail V.
Publicado: (2017)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury
por: Petrache, Irina, et al.
Publicado: (2021)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
por: Valianou, Matthildi, et al.
Publicado: (2019)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Practical way of creating differential diagnoses through an expanded VITAMINSABCDEK mnemonic
por: Zabidi-Hussin, Zabidi A
Publicado: (2016)

Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis
por: Islam, Md. Asiful, et al.
Publicado: (2017)

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Tuberous sclerosis
por: George, Anisha, et al.
Publicado: (2015)

Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
por: Shi, Guoli, et al.
Publicado: (2022)

In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors
por: Zulkipli, Ninie Nadia, et al.
Publicado: (2020)

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin
por: Koenig, Mary Kay, et al.
Publicado: (2012)

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway
por: Hartman, Tiffiney R., et al.
Publicado: (2009)

Tuberous sclerosis complex associated lymphangioleiomyomatosis
por: Han, Z, et al.
Publicado: (2023)

AUTISM IN TUBEROUS SCLEROSIS
por: Khanna, Rakesh, et al.
Publicado: (1991)

Tuberous sclerosis with rhabdomyoma
por: Ajay, V., et al.
Publicado: (2013)

Tuberous (or Tuberose) Sclerosis
por: Fowler, J. S., et al.
Publicado: (1910)

Cannot write session to /tmp/vufind_sessions/sess_hooafcqo331ag88m3umel1vths